# Nuclidium

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuclidium

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.nuclidium.com
- Total disclosed funding: $132M
- Latest round: Series B (May 21, 2026)
- Investors on record: 12

## About

Founded in 2017 and based in Basel, Switzerland, Nuclidium AG, formerly known as Swiss Nuclides AG, operates as a biopharmaceutical company that develops and manufactures drugs for the treatment of cancer. Leila Jaafar (CEO) and Gustav von Schulthess are the co-founders of the company.  In May 2026, Nuclidium AG raise CHF 26 million in series B funding co-le by Angelini Ventures and Kurma Partners, with participation from investors European Investment Bank, Bayern Kapital, DeepTech and Climate Fund, Neva, NRW Bank, Vives, and Wellington Partners.
 The company will use the funding to accelerate clinical development of its lead programs, expand manufacturing and production capabilities, and advance additional preclinical targets. The company offers CuTrace™ platform, which integrates copper radiometals with a variety of cancer-targeting compounds to generate novel therapeutic and diagnostic solutions. Nuclidium’s pipeline include NuriPro ™ for prostate cancer, TraceNET ™ for neuroendocrine tumors, Kalios ™ for colorectal, gastric, and lobular breast cancer, CuNeo ™ for ductal breast and lung cancer, and AlphaFlare ™ for head and neck pancreatic cancer. The firm’s pipeline comprises of tumor indications and copper-based radiopharmaceuticals.

## Funding rounds

- Series B, May 21, 2026, $33M — Wellington Partners, Vives, NRW Bank, European Investment Bank, Kurma Partners, Bayern Kapital, Neva, Angelini Ventures, DeepTech and Climate Fund
- Series B, Jun 1, 2025, $96M — Wellington Partners, Eurazeo, Vives, NRW Bank, Kurma Partners, Bayern Kapital, HighLight Capital, Neva, Angelini Ventures, DeepTech and Climate Fund
- Series A, Jun 21, 2021, $2.8M — Turos Capital

## Investors

- Turos Capital (https://capitalatlas.ai/funds/turos-capital) — Series A
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series B
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series B
- Vives (https://capitalatlas.ai/funds/vives) — Series B
- NRW Bank — Series B
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series B
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Neva (https://capitalatlas.ai/funds/neva) — Series B
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series B
- DeepTech and Climate Fund (https://capitalatlas.ai/funds/deeptech-and-climate-fund) — Series B
- European Investment Bank (https://capitalatlas.ai/funds/european-investment-bank) — Series B